Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors

Next Previous
Trial Profile

Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms S-PLAT study

    • Most Recent Events

    • 04 Feb 2019 Status changed from recruiting to active, no longer recruiting.
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top